knowledge -WSS

knowledge

author：focus 2025-09-30 06:12:56 Page View：2

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hospitals, health systems can help patients avoid medical debt
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

leisure time

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Pregnancy discrimination could be enabled by AI

AdobeInJune2023,thePregnantWorkersFairnessAct(PWFA)wentintoeffect.Thefederallawrequiresemployerstogi

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Leukemia patients are helped by Syndax's new type of therapy

AdobeSANDIEGO—OneofthetoughestsubtypesofacuteleukemiainvolvesageneticalterationintheKMT2Agene.Manyca

knowledge

explore

leisure time

Leukemia patients are helped by Syndax's new type of therapy